Riluzole Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis: Texture and Compatibility with Food Thickeners Evaluation

Riluzole Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis: Texture and Compatibility with Food Thickeners Evaluation

Riluzole 5 mg/mL oral suspension is the only licensed liquid medicine to treat Amyotrophic Lateral Sclerosis (ALS) orally. As more than 80% of ALS patients develop dysphagia, an oral liquid formulation provides an important therapeutic option. The Riluzole 5 mg/mL oral suspension is administered by...

Full description

Bibliographic Details
Main Authors: Giuseppe Colombo, Roberta Artico, Daniele Barbareschi
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:J
Subjects:
ALS
dysphagia
Riluzole oral suspension
HPLC
patient compliance
liquid formulation
Online Access:https://www.mdpi.com/2571-8800/3/3/21

Internet

https://www.mdpi.com/2571-8800/3/3/21

Similar Items